


LITERATURA

1. Ampapa R. Kognitivní dysfunkce u sekundárně progresivní roztroušené sklerózy. *Neurol. praxi.* 2022;23(3):221-226. doi: 10.36290/neu.2021.094.
2. Beckmann YY, Gelal F, Eren Ş, et al. Diagnostics to Look beyond the Normal Appearing Brain Tissue (NABT)? A Neuroimaging Study of Patients with Primary Headache and NABT Using Magnetization Transfer Imaging and Diffusion Magnetic Resonance. *Clin. Neuroradiol.* 2013;23(4):277-283. doi: 10.1007/s00062-013-0203-4.
3. Behrang N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. *Cells.* 2019;8(1):24. doi: 10.3390/cells8010024.
4. Benedict RHB, Amato MP, DeLuca J, et al. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. *Lancet Neurol.* 2020;19(10):860-871. doi: 10.1016/S1474-4422(20)30277-5.
5. Benedict RHB, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. *Mult Scler.* 2017;23:721-733. doi: 10.1177/1352458517690821.
6. Benedict RHB, Penner IK, Kappos L, et al. Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 EXPAND study (2275). *Neurology.* 2021a;96(15 Supplement):2275.
7. Benedict RHB, Tomic D, Cree BA, et al. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses. *Neurology.* 2021 b;96(3):e376-e386. doi: 10.1212/WNL.00000000000011275.
8. Cavado E, Tran P, Thoprakarn U, et al. Validation of an automatic tool for the rapid measurement of brain atrophy and white matter hyperintensity: QyScore®. *Eur. Radiol.* 2022;32(5):2949-2961. doi: 10.1007/s00330-021-08385-9.
9. Grzegorski T, Losy J. Cognitive impairment in multiple sclerosis - a review of current knowledge and recent research. *Rev Neurosci.* 2017;28(8):845-860. doi: 10.1515/revneuro-2017-0011.
10. Hynčicová E., Meluzimová E., Laczó J. Kognice a roztroušená skleróza. *Neurol. praxi.* 2017;18(6):394-398. doi: 10.36290/neu.2018.055.
11. Kappos L, Bar-Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet.* 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6.
12. Leavitt VM, Brandstadter R, Fabian M, et al. Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. *Mult Scler.* 2020;26(10):1247-1255. doi:10.1177/1352458519860319.
13. Linnhoff S, Fiene M, Heinze HJ, et al. Cognitive Fatigue in Multiple Sclerosis: An Objective Approach to Diagnosis and Treatment by Transcranial Electrical Stimulation. *Brain Sci.* 2019;9(5):100. doi: 10.3390/brainsci9050100.
14. Paphathanasiou A, Messinis L, Georgiou VL, et al. Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery. *ISRN Neurol.* 2014;2014:151379. doi: 10.1155/2014/151379.
15. Patten SB, Ruth AM, Mauro GC. Depression in multiple sclerosis. *Int Rev Psychiatry.* 2017;29(5):463-472. doi: 10.1080/09540261.2017.1322555.
16. Petracca M, Saiote C, Bender H, et al. Synchronization and variability imbalance underlie cognitive impairment in primary-progressive multiple sclerosis. *Sci Rep.* 2017;7:46411. doi: 10.1038/srep46411.
17. Pitteri M, Romualdi C, Magliozzi R, et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study. *Mult Scler.* 2017;23(6):848-854. doi: 10.1177/1352458516665496.
18. Popescu V, Klaver R, Voorn P, et al. What drives MRI-measured cortical atrophy in multiple sclerosis? *Mult. Scler. J.* 2015;21(10):1280-1290. doi: 10.1177/1352458514562440.
19. Rocca MA, Amato MP, De Stefano N, et al. MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. *Lancet Neurol.* 2015;14(3):302-17. doi: 10.1016/S1474.
20. Sandroff BM, Schwartz CE, DeLuca J. Measurement and maintenance of reserve in multiple sclerosis. *J Neurol.* 2016; 263(11):2158-2169. doi: 10.1007/s00415-016-8104-5.
21. Schependom VJ, Nagels G. Targeting Cognitive Impairment in Multiple Sclerosis – The Road toward an Imaging-based Biomarker. *Front. Neurosci.* 2017;11. doi: 10.3389/fnins.2017.00380.
22. Stern Y. Cognitive reserve. *Neuropsychologia.* 2009;47(10):2015-2028. doi: 10.1016/j.neuropsychologia.2009.03.004.
23. Strádálová P, Štourač P, Králíčková N, Kvapilová E. Ochranné faktory kognitivního deficitu u roztroušené sklerózy. *Cesk Slov Neurol N.* 2018;81(1):24-28. doi: 10.14735/amcsnn201824.
24. Sumowski JF. Cognitive reserve as a useful concept for early intervention research in multiple sclerosis. *Front. Neurol.* 2015;6:176. doi: 10.3389/fneur.2015.00176.
25. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. *Neurology.* 2016;86(21):2006-2009. doi:10.1212/WNL.0000000000002702.
26. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it. *Neurology.* 2013;80(24):2186-2193. doi: 10.1212/WNL.0b013e318296e98b.
27. Sumowski JF, Rocca MA, Leavitt VM et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. *Neurology.* 2014;82(20):1776-1783. doi: 10.1212/WNL.0000000000000433.
28. Vaněčková M, Seidl Z, Krásenský J, et al. Naše zkušenosti s MR monitorováním pacientů s roztroušenou sklerózou v klinické praxi. *Cesk Slov Neurol N.* 2010;73/106(6):716-720.



21. symposium praktické neurologie

6.–7. 6. 2024
BRNO



Aktuální program sledujte na
www.neubрно.cz

MÍSTO KONÁNÍ:
Hotel International Brno
Husova 200/16, 602 00 Brno

